Pfizer stock: FDA expands Tukysa’s breast cancer approval
Pfizer’s new Tukysa FDA approval follows an 11% U.S. sales decline in Q2. What the label changes, its 0.9% revenue share and the November 3 earnings checkpoint.
Tag
#Healthcare Stocks
2 articles
TECHi reporting and analysis covering Healthcare Stocks. 2 articles, newest first.
Abbott (ABT) Stock Price Prediction 2027: Analyst Targets, Q1 2026 Earnings & Bull/Bear Scenarios
Abbott (ABT) stock at $95.47 after Q1 2026 guidance cut. Analyst consensus $134 target, 40% upside. Full 2027 bull/bear/base case forecast.